Skip to content

HIV-positive patients who receive therapy for acute HCV can be cured with just 24 weeks of therapy

HIV-positive patients have good long-term responses to hepatitis A vaccination

Gene associated with increased risk of cirrhosis for HIV/HCV-co-infected patients

US approval for hepatitis C drug telaprevir

European approval recommended for hepatitis C drug boceprevir

Genetic variation associated with response to hepatitis C therapy in HIV co-infected patients

HIV treatment preserves CD4 cell count during and after HCV therapy in co-infected patients

Twice-weekly pegylated interferon improved early treatment responses in co-infected patients

High rate of liver fibrosis progression in HIV-positive patients, but signs that earlier initiation of antiretrovirals protective